<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01708057</url>
  </required_header>
  <id_info>
    <org_study_id>D1883C00007</org_study_id>
    <secondary_id>EudraCT number: 2012-002900-42</secondary_id>
    <nct_id>NCT01708057</nct_id>
  </id_info>
  <brief_title>A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Randomised, Double-blind Placebo- and Active-controlled, Multi-centre, 6-way Cross-over, Single-dose Phase IIa Study to Investigate the Bronchodilatory and Systemic Effects of 4 Different Doses of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the
      bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active
      comparator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind placebo- and active-controlled, multi-centre, 6-way cross-over,
      single-dose phase IIa study to investigate the bronchodilatory and systemic effects of 4
      different doses of inhaled AZD8683 in patients with Chronic Obstructive Pulmonary Disease
      (COPD).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Peak FEV1 (0-24h)</measure>
    <time_frame>The first 24 hours following dose administration</time_frame>
    <description>The maximum value over 24 hours post-dose, as change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 (22-26h)</measure>
    <time_frame>22 to 26 hours following dose administration</time_frame>
    <description>The average over 22 to 26 hours, as change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 as a Change From Baseline</measure>
    <time_frame>The first 24 hours following dose administration</time_frame>
    <description>Average FEV1 (0-24h): The average over 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Increase in Systolic Blood Pressure [SBP]</measure>
    <time_frame>baseline, 24hr post dose</time_frame>
    <description>Maximum (post-dose values - baseline value) for each treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Increase in Diastolic Blood Pressure [DBP]</measure>
    <time_frame>The first 24 hours following dose administration</time_frame>
    <description>Maximum (post-dose values - baseline value) for each treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Increase Heart Rate [HR]</measure>
    <time_frame>baseline, 24hr post dose</time_frame>
    <description>Maximum (post-dose values - baseline value) for each treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Increase in QTcF</measure>
    <time_frame>baseline, 24hr post dose</time_frame>
    <description>maximum (post-dose values - baseline value) for each treatment visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters (AZD8683)</measure>
    <time_frame>Pre-dose, 24hr post-dose</time_frame>
    <description>Cmax, tmax, AUC</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD8683 50 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD8683 150 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD8683 300 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD8683 900 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of tiotropium 18 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8683</intervention_name>
    <description>AZD8683 administered via inhalation</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered via inhalation</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium administered via inhalation</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures Male or female,
             age ≥ 40 years at Visit 1. Women must be of non-childbearing potential or must have
             been stable on a highly effective contraceptive method for at least 3 months prior to
             Visit 1 and be willing to continue until follow-up

          -  Clinical diagnosis of COPD for more than 1 year at Visit 1

          -  FEV1 ≥ 30 to &lt; 80% of the predicted normal value (post-bronchodilator) at Visit 2 and
             post-bronchodilator FEV1/FVC &lt; 70%

          -  Reversible airway obstruction

        Exclusion Criteria:

          -  Significant disease or disorder which, in the opinion of the Investigator, may either
             put the patient at risk because of participation in the study, or influence the result
             of the study, or the patient's ability to participate in the study.

          -  An exacerbation of COPD (defined as use of oral/parenteral glucocorticosteroids (GCS)
             and/or antibiotics and/or hospitalisation related to COPD) within 6 weeks of Visit 1or
             during the enrolment period

          -  Treatment with systemic GCS within 6 weeks of Visit 2 or during the enrolment period

          -  Respiratory tract infection of clinical relevance within 30 days of Visit 4, as judged
             by the Investigator

          -  Long-term oxygen therapy, as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;DMolndal, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <results_first_submitted>July 30, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2013</results_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 14 subjects were enrolled. Of these, 3 subjects were randomized to receive a treatment sequence consisting of 6 different treatments in random order. The study was terminated prematurely, hence only one period out of six planned was performed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AFBECD</title>
          <description>AZD8683 50 ug followed by Placebo followed by AZD8683 150 ug followed by Spiriva® 18 ug followed by AZD8683 300 ug followed by AZD8683 900 ug</description>
        </group>
        <group group_id="P2">
          <title>FEADBC</title>
          <description>Placebo followed by Spiriva® 18 ug followed by AZD8683 50 ug followed by AZD8683 900 ug followed by AZD8683 150 ug followed by AZD8683 300 ug</description>
        </group>
        <group group_id="P3">
          <title>DCEBFA</title>
          <description>AZD8683 900 ug followed by AZD8683 300 ug followed by Spiriva® 18 ug followed by AZD8683 150 ug followed by Placebo followed by AZD8683 50 ug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal due to study termination.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Baseline</title>
          <description>All Patients population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Peak FEV1 (0-24h)</title>
        <description>The maximum value over 24 hours post-dose, as change from baseline</description>
        <time_frame>The first 24 hours following dose administration</time_frame>
        <population>As the study was terminated prematurely none of the randomised patients have been analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak FEV1 (0-24h)</title>
          <description>The maximum value over 24 hours post-dose, as change from baseline</description>
          <population>As the study was terminated prematurely none of the randomised patients have been analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 (22-26h)</title>
        <description>The average over 22 to 26 hours, as change from baseline</description>
        <time_frame>22 to 26 hours following dose administration</time_frame>
        <population>As the study was terminated prematurely none of the randomized patients have been analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 (22-26h)</title>
          <description>The average over 22 to 26 hours, as change from baseline</description>
          <population>As the study was terminated prematurely none of the randomized patients have been analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average FEV1 as a Change From Baseline</title>
        <description>Average FEV1 (0-24h): The average over 0 to 24 hours</description>
        <time_frame>The first 24 hours following dose administration</time_frame>
        <population>As the study was terminated prematurely none of the randomized patients have been analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Average FEV1 as a Change From Baseline</title>
          <description>Average FEV1 (0-24h): The average over 0 to 24 hours</description>
          <population>As the study was terminated prematurely none of the randomized patients have been analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Increase in Systolic Blood Pressure [SBP]</title>
        <description>Maximum (post-dose values - baseline value) for each treatment visit.</description>
        <time_frame>baseline, 24hr post dose</time_frame>
        <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase in Systolic Blood Pressure [SBP]</title>
          <description>Maximum (post-dose values - baseline value) for each treatment visit.</description>
          <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Increase in Diastolic Blood Pressure [DBP]</title>
        <description>Maximum (post-dose values – baseline value) for each treatment visit.</description>
        <time_frame>The first 24 hours following dose administration</time_frame>
        <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase in Diastolic Blood Pressure [DBP]</title>
          <description>Maximum (post-dose values – baseline value) for each treatment visit.</description>
          <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Increase Heart Rate [HR]</title>
        <description>Maximum (post-dose values – baseline value) for each treatment visit.</description>
        <time_frame>baseline, 24hr post dose</time_frame>
        <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase Heart Rate [HR]</title>
          <description>Maximum (post-dose values – baseline value) for each treatment visit.</description>
          <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Increase in QTcF</title>
        <description>maximum (post-dose values – baseline value) for each treatment visit.</description>
        <time_frame>baseline, 24hr post dose</time_frame>
        <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Increase in QTcF</title>
          <description>maximum (post-dose values – baseline value) for each treatment visit.</description>
          <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameters (AZD8683)</title>
        <description>Cmax, tmax, AUC</description>
        <time_frame>Pre-dose, 24hr post-dose</time_frame>
        <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD8683 150 ug</title>
            <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O2">
            <title>AZD8683 300ug</title>
            <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
          <group group_id="O3">
            <title>AZD8683 900ug</title>
            <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler</description>
          </group>
          <group group_id="O4">
            <title>Spiriva 18 ug</title>
            <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
          </group>
          <group group_id="O6">
            <title>AZD8683 50ug</title>
            <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameters (AZD8683)</title>
          <description>Cmax, tmax, AUC</description>
          <population>As the study was terminated prematurely none of the randomised patients have bean analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50ug AZD8683</title>
          <description>AZD8683 50 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
        </group>
        <group group_id="E2">
          <title>150 ug AZD8683</title>
          <description>AZD8683 150 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
        </group>
        <group group_id="E3">
          <title>300 ug AZD8683</title>
          <description>AZD8683 300 ug via Turbuhaler + Turbuhaler Placebo +Handihaler Placebo for Spiriva</description>
        </group>
        <group group_id="E4">
          <title>900 ug AZD8683</title>
          <description>AZD8683 900 ug via Turbuhaler + placebo for Spiriva via HandiHaler;</description>
        </group>
        <group group_id="E5">
          <title>18ug Spiriva</title>
          <description>Turbuhaler® Placebo+Handihaler® Spiriva® 18 μg</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Turbuhaler® Placebo+Handihaler® Placebo for Spiriva®</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carin Jorup</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

